These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 27143148)

  • 1. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
    Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
    J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of selective first-line use of biologics for unresectable
    Wong WWL; Zargar M; Berry SR; Ko YJ; Riesco-Martínez M; Chan KKW
    Curr Oncol; 2019 Oct; 26(5):e597-e609. PubMed ID: 31708653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
    Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M
    Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
    Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L
    Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
    Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
    Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
    Shi Y; Wan X; Tan C; Li J; Peng L
    Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
    Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
    BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of
    Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V
    J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
    Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Rivera F; Valladares M; Gea S; López-Martínez N
    J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
    Miyazaki Y; Harada T; Akase T; Arakawa I; Inoue T
    Clin Ther; 2009; 31 Pt 2():2433-41. PubMed ID: 20110051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
    Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
    Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
    Pericay C; Frías C; Abad A; Lamas MJ; Echave M; Oyagüez I; Rubio M; Giménez E; Naoshy S; Joulain F
    Farm Hosp; 2014 Jul; 38(4):317-27. PubMed ID: 25137165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
    Parikh RC; Du XL; Robert MO; Lairson DR
    J Manag Care Spec Pharm; 2017 Jan; 23(1):64-73. PubMed ID: 28025930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.